Showing posts with label MRI. Show all posts
Showing posts with label MRI. Show all posts

Monday, November 10, 2008

Multiple Sclerosis Progression Can Be Predicted With MRI





ScienceDaily (Nov. 6, 2008) — A new study published in Journal of Neuroimaging shows that MRI scans used on multiple sclerosis (MS) patients to determine if the disease has affected gray matter in the brain can identify those at-risk for progression of disability.

MS affects approximately 400,000 people in the United States and as many as 2.5 million worldwide. It is the most common cause of progressive disability in young adults. While the cause of the disease remains unknown, it is characterized by damage to the covering over the nerve fibers in the brain and spinal cord, or to the nerve fiber itself.

In an attempt to understand the causes of disease progression, researchers at the Partners MS Center, led by Dr. Rohit Bakshi and his team, have developed new ways to detect gray matter damage.

Dr. Bakshi, Director of the Laboratory for Neuroimaging Research and an Associate Professor of Neurology and Radiology at the Brigham and Women's Hospital and Harvard Medical School, led a four year follow-up study, which found that patients with unnatural darkness of gray matter structures as seen on MRI pictures carried a higher risk for progression of physical disability. This abnormal darkness is referred to as T2 hypointensity, and is suggestive of excessive iron deposits. In addition, the researchers found that the new marker of gray matter damage showed closer correlations with patients' clinical status than other established MRI markers of disease severity, including lesions, also known as "plaques," and shrinkage of the brain, also know as "atrophy."

"MRI scans obtained from patients with MS are being used to develop measures and techniques that can accurately measure the visible and hidden damage to the brain, especially in gray matter areas and can more accurately predict the course of the disease," says Bakshi.

As a result of the findings, MRI-based measurement of gray matter damage may be used as a surrogate marker of disease progression. Physicians may therefore be able to more accurately identify patients at risk for developing this progressive disease.

MS has been traditionally viewed as a disease affecting the white matter of the brain, where messages are transferred between the brains gray matter sections, which control the processing of information. While prior research has shown that the brain's gray matter is also affected, studies detailing its effects have been limited. In addition, current therapies for MS are incomplete, raising the need to better understand disease mechanisms and the biomarkers of disease progression. If excessive iron in gray matter contributes to damage, this would open a new avenue for developing better therapies.

Journal reference:

1. Neema et al. Deep Gray Matter Involvement on Brain MRI Scans Is Associated with Clinical Progression in Multiple Sclerosis. Journal of Neuroimaging, 2008; DOI: 10.1111/j.1552-6569.2008.00296.x

Adapted from materials provided by Wiley-Blackwell, via EurekAlert!, a service of AAAS.
Need to cite this story in your essay, paper, or report? Use one of the following formats:
APA

MLA
Wiley-Blackwell (2008, November 6). Multiple Sclerosis Progression Can Be Predicted With MRI. ScienceDaily. Retrieved November 10, 2008, from http://www.sciencedaily.com­ /releases/2008/11/081105164308.htm

Wednesday, October 01, 2008

Magnetic Resonance Imaging Can Predict Who Will Develop Multiple Sclerosis: Presented at WCTRMS





By Louise Gagnon

MONTREAL -- September 24, 2008 -- Specific magnetic resonance imaging (MRI) scans can predict which patients will develop multiple sclerosis (MS), according to retrospective research presented here at the World Congress on Treatment and Research in Multiple Sclerosis (WCTRMS).

The Betaferon/Betaseron in Newly Emerging MS for Initial Treatment (BENEFIT) study is a randomised, double-blind, placebo-controlled, parallel-group clinical trial that was carried out among 468 patients whose first clinical event suggestive of MS happened within 60 days of trial entry. The study found that treatment with interferon (INF) beta-1b 250 mcg prevented the onset of clinically definite multiple sclerosis (CDMS) by 1 year.

Patients in the BENEFIT study were assigned to either early treatment, which was IFN beta-1b from the start of the trial, or delayed treatment, which was initial placebo followed by IFN beta-1b therapy after conversion to CDMS or upon completing 2-year follow-up.

Principal investigator Bastiaan Moraal, MD, VU Medical Center, Amsterdam, Netherlands, speaking at an oral session here on September 19, said that this analysis examined radiological rather than clinical endpoints.

"We were looking at which type of lesions measured at baseline would predict conversion to clinically definite multiple sclerosis or McDonald multiple sclerosis," said Dr. Moraal.

In this analysis, blinded raters assessed baseline MRI parameters using T2-weighted and postcontrast T1-weighted sequences. Statistical analysis was employed to assess the predictive value of each baseline MRI parameter and treatment interaction.

Investigators found overall conversion to CDMS was 42%, with factors such as the presence of =>9 T2 lesions and =>3 periventricular lesions demonstrating predictive value. They found that conversion rose with the cumulative number of positive criteria. No specific advantage was demonstrated for a threshold of =>3 Barkhof criteria.

"Patients whose treatment was delayed and had 4 positive Barkhof criteria had a higher chance of conversion to CDMS and McDonald MS compared to those with early treatment and fewer positive Barkhof criteria at baseline," explained Dr. Moraal.

Investigators found that prognostic value was affected by treatment (P = .002) for 4 positive Barkhof criteria. The prognostic value was not influenced by therapy for CDMS.

"We saw that, with one exception, the predictive value of MRI values was not affected by treatment," said Dr. Moraal.

Future analysis will examine the predictive value of MRI variables at 3, 6, and 9 months to assess the impact of those variables on conversion to either CDMS or McDonald MS.


[Presentation title: Baseline Magnetic Resonance Imaging Predictors for Conversion to Clinically Definite Multiple Sclerosis and McDonald Multiple Sclerosis, Based on Integrated 3-Year Data From the BENEFIT Study. Abstract 51]

Saturday, August 02, 2008

Multiple Sclerosis: New MRI Contrast Medium Enables Early Diagnosis In Animal Model





ScienceDaily (Aug. 1, 2008) — In an animal model of multiple sclerosis (MS), neuroradiologists and neurologists of the University hospitals of Heidelberg and Würzburg have been able to visualize inflammatory tissue damage, most of which had remained unrecognized up to now, with the aid of a new contrast medium, Gadofluorine M, in magnetic resonance imaging.

In particular at the early stage of the disease, drug treatment is effective. Up to now, how-ever, an early diagnosis is frequently not established with certainty, especially if no (or very few) inflammatory lesions are present on MRI. "With this new contrast medium, we were able to visualize five to ten times more foci of inflammation in comparison to conventional MRI images and contrast media", reports Professor Dr. Martin Bendszus, Medical Director of the Department of Neuroradiology at the University hospital of Heidelberg.

Previously unrecognized patches of demyelination visible in MRI

MS is a chronic inflammatory disease of the central nervous system of unknown cause. It usually begins in young adults, and women are affected more frequently. In Germany, ap-proximately 120,000 patients are afflicted. MS is characterized by multiple inflammatory le-sions in which nerve fibers lose their myelin sheath. These patches of demyelination cause neurological malfunctions that may regress upon remyelination. At later stages, MS may re-sult in a loss of nerve fibers, leading to irreversible damage and persistent neurological symptoms. MRI plays a crucial role in the early diagnosis of MS and monitoring of the dis-ease.

The scientists from Heidelberg and Würzburg examined brains and spinal cords of animals at different stages of the disease with the new contrast medium and found significantly more inflammatory lesions than with conventional contrast media. Examinations of tissue sections from these lesions showed that these were actually foci of inflammation. The application of this new contrast medium was clearly superior to conventional contrast media, especially for the spinal cord or optical nerve, nerve regions that are particularly difficult to examine on MRI.

New contrast medium accumulates better in MS lesions

The results of the study could help dramatically improve the diagnostic work-up in MS with a potential impact on early treatment. "MS is the most frequent cause of occupational disability and handicap in young adults", explains Professor Bendszus. "New therapies have a positive influence on the course of the disease, but are often not initiated at early stages since the diagnosis of MS is not yet established. "

The new contrast medium gadofluorine M supposedly visualizes MS lesions better because it binds especially well to certain components of the extracellular matrix of inflammatory foci. Because of this, it accumulates in these lesions in higher concentrations.

Now, the next objective of the interdisciplinary working group is to further develop the new MRI contrast medium for application in clinical practice. As of now, the contrast medium is not yet approved. Additional preclinical tests are necessary for the planned clinical application.

Journal reference:

1. Bendszus et al. Gadofluorine M enhancement allows more sensitive detection of inflammatory CNS lesions than T2-w imaging: a quantitative MRI study. Brain, 2008; DOI: 10.1093/brain/awn156

Adapted from materials provided by University Hospital Heidelberg, via EurekAlert!, a service of AAAS.

Tuesday, November 13, 2007

MR Imaging Intensity Modeling of Damage and Repair In Multiple Sclerosis: Relationship of Short-Term Lesion Recovery to Progression and Disability



American Journal of Neuroradiology 28:1956-1963, November-December 2007
© 2007 American Society of Neuroradiology

D.S. Meier, Department of Radiology, Center for Neurological Imaging, Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School, Boston Mass

H.L. Weiner, Department of Neurology, Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School, Boston Mass

C.R.G. Guttmann, Department of Radiology, Center for Neurological Imaging, Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School, Boston Mass

Please address correspondence to Dominik Meier, PhD, Center for Neurological Imaging, Brigham and Women's Hospital, 221 Longwood Ave, RF 396, Boston, MA 02115; e-mail: meier@bwh.harvard.edu


BACKGROUND AND PURPOSE: Formation of lesions in multiple sclerosis (MS) shows pronounced short-term fluctuation of MR imaging hyperintensity and size, a qualitatively known but poorly characterized phenomenon. With the use of time-series modeling of MR imaging intensity, our study relates the short-term dynamics of new T2 lesion formation to those of contrast enhancement and markers of long-term progression of disease.

MATERIALS AND METHODS: We analyzed 915 examinations from weekly to monthly MR imaging in 40 patients with MS using a time-series model, emulating 2 opposing processes of T2 prolongation and shortening, respectively. Patterns of activity, duration, and residual hyperintensity within new T2 lesions were measured and evaluated for relationships to disability, atrophy, and clinical phenotype in long-term follow-up.

RESULTS: Significant T2 activity was observed for 8 to 10 weeks beyond contrast enhancement, which suggests that T2 MR imaging is sensitive to noninflammatory processes such as degeneration and repair. Larger lesions showed longer subacute phases but disproportionally more recovery. Patients with smaller average peak lesion size showed trends toward greater disability and proportional residual damage. Higher rates of disability or atrophy were associated with subjects whose lesions showed greater residual hyperintensity.

CONCLUSION: Smaller lesions appeared disproportionally more damaging than larger lesions, with lesions in progressive MS smaller and of shorter activity than in relapsing-remitting MS. Associations of lesion dynamics with rates of atrophy and disability and clinical subtype suggest that changes in lesion dynamics may represent a shift from inflammatory toward degenerative disease activity and greater proximity to a progressive stage, possibly allowing staging of the progression of MS earlier, before atrophy or disability develops.

Thursday, August 30, 2007

Possible New MRI Marker for Multiple Sclerosis Progression





By Crystal Phend, Staff Writer, MedPage Today
Reviewed by Zalman S. Agus, MD; Emeritus Professor at the University of Pennsylvania School of Medicine.

BOSTON, Aug. 28 -- Bright spots commonly seen on T1 magnetic resonance imaging brain scans of multiple sclerosis patients may help predict risk of disease progression, researchers here said.

The number of these hyperintense lesions was also significantly correlated with physical disability (P=0.04) and brain atrophy (P≤0.001), found Rohit Bakshi, M.D., of Harvard and Brigham and Women's Hospital, and colleagues.

The findings of their retrospective study suggest that these lesions could be a new clinically relevant biomarker for multiple sclerosis, they wrote in the September issue of the journal Radiology.

Hyperintense lesions on T2-weighted MRI have been used for diagnosis and monitoring of multiple sclerosis, but the clinical correlations have seemed weak, they noted.

"Clearly, there is a need for better MRI markers of disease activity and tissue damage," they wrote.

So, the researchers retrospectively reviewed a database of 145 consecutive multiple sclerosis patients referred to a community-based comprehensive MS center from 1995 to 1999.

The majority of patients were women (77%) and had relapsing-remitting multiple sclerosis (63%). The remaining 34% had secondary-progressive disease. Those with primary-progressive disease were excluded. The mean disease duration was 9.6 years.

Two researchers blinded to patients' clinical details reviewed MRIs from each patient and found that 78% had T1 hyperintense lesions with a mean of 2.3 lesions per patient.

The lesions were typically seen in the supratentorial regions of the brain, particularly the superior and inferior frontal lobes and the superior parietal lobe.

More than a third of the lesions showed up with uniform hyperintensity (38%), but the majority showed hyperintensity only around the rim of the lesion (62%). The average diameter was 0.8 cm.

Patients with more advanced clinical disease were significantly more likely to have multiple than single T1 hyperintense lesions (P<0.001). The findings were:

71% of patients with secondary progressive disease had multiple lesions whereas only 8% had single lesions.
46% of patients with relapsing-remitting disease had multiple lesions whereas 30% had single lesions.

Total number of T1 hyperintense lesions was also significantly correlated with more advanced disease (P=0.003), although the number of T2 hyperintense lesions was not (P=0.059).

"Thus, only the T1 hyperintense lesion subtype was associated with advancing clinical disease course," the researchers noted.

The same pattern was seen for physical disability and brain atrophy, in which T1 lesions were weak-to-moderate predictors but significant whereas T2 lesions were not.

The researchers found that the total number of T1 hyperintense lesions was significantly correlated with physical disability score on the Expanded Disability Status Scale (P=0.04), whereas the total number of T2 hyperintense lesions was not (P=0.14).

Total cortical brain atrophy was significantly associated with the total number of T1 hyperintense lesions on univariate analysis (P<0.001) and after adjusting for disease course (P=0.001).

Another measure of brain atrophy, third ventricular width, was also associated with the total number of T1 hyperintense lesions on univariate analysis (P<0.001) and after controlling for disease course (P=0.001).

The researchers noted that the findings were limited by the use of various MRI protocols across the retrospectively examined cohort, including inconsistent use of contrast-material enhanced imaging, the cross-sectional design that did not allow study of the evolution of T1 hyperintense lesions, and the lack of a quantitative analysis of T1 hyperintensity or relaxation time.

Prospective studies are needed to evaluate multiple T1 protocols, "to see whether the effect is technically dependent;" to incorporate newer techniques, such as diffusion-tensor imaging and MR spectroscopy; and to assess prediction of clinical progression, they said.

"On the basis of these limitations, we urge caution that the results and conclusion of this study should be treated as exploratory and require confirmation in a larger prospective study," they wrote.

Meanwhile, they suggested that physicians should look for hyperintense lesions on nonenhanced T1-weighted MR images "as these may provide useful diagnostic information."

"For the proper evaluation of the presence of gadolinium-based contrast agent enhancement on contrast-enhanced images," they added, "nonenhanced images should be examined concurrently to determine whether hyperintensity on contrast-enhanced images is related to enhancement or to intrinsic T1 shortening in lesions."

Dr. Bakshi reported support in part by grants from the National Institute of Neurological Disorders and Stroke, the National Multiple Sclerosis Society, and the National Science Foundation. The researchers reported no conflicts of interest.
Additional Multiple Sclerosis Coverage

Primary source: Radiology
Source reference:
Janardhan V, et al "Multiple Sclerosis: Hyperintense Lesions in the Brain on Nonenhanced T1-weighted MR Images Evidenced as Areas of T1 Shortening" Radiology 2007;244:823-831.

Tuesday, June 05, 2007

Seeing The Brain Like Never Before

University Of Michigan team uses MRI scans to help surgeons avoid crucial "white matter" links, because the brain is a very complicated place.

From the outside, it may look like a gray lump of tissue, covered with ridges and bumps. But inside, an incredibly complex network of thread-like white fibers carries signals back and forth between areas of the brain and the spinal cord. Each fiber is crucial to a particular aspect of how our mind communicates with our body.

But until now, brain surgeons haven't been able to see those fibers, called white-matter tracts. Invisible to the naked eye, and impossible to see on normal brain scans, they fall victim to even the most careful surgeon's hand during operations to remove tumors or calm severe epilepsy. And the result can be permanent, unintended damage to the senses, movement, or thinking ability.

Now, advanced medical imaging is making it possible for surgeons to know where those tracts are – and even to see them in their field of vision while they operate.

A University of Michigan Health System team is one of the first in the world to offer this type of image-guided surgery. Already, it has helped them plan the operations of patients, and reduce their risk of damage. And the technique holds great promise for other uses as it is developed further.

"In the past, we had a pretty good idea of what different parts of the brain do, but we've never been able to see the direct connections from one part of the brain to another, or from one part of the brain to the spinal cord," says one of the team's leaders, Suresh Mukherji, M.D. "We can see those connections now, by looking at the sub-cellular level to see how the water molecules in the tissue move."

Mukherji directs the U-M Division of Neuroradiology – a team of brain-imaging specialists. They work closely with U-M neurosurgeons, who perform thousands of brain and spine operations a year, and with neurologists who diagnose and treat brain and nerve disorders ranging from epilepsy and multiple sclerosis to cancer.

Neurosurgeon Oren Sagher, M.D., says this teamwork makes it possible for him to operate with the best possible information about each patient's brain. "Thoroughly imaging the brain is one of the keys to successful brain surgery. We have to be able to see all the structures that we're going after, and all the structures that are in our way and need to be avoided," he says.

That's what the new imaging technique, called tractography, makes possible for the first time.

The technique relies on powerful MRI (magnetic resonance imaging) scanners, which create images of patients' brains, one thin slice at a time. U-M has several extremely powerful MRI machines, call 3T scanners.

Then, ultra-fast computers equipped with special software compile all of those slices into a three-dimensional image of the brain. Lastly, the neuroimaging team uses special techniques to see how water molecules are moving inside every area of that virtual 3-D brain.

It's that water-movement imaging that allows the white-matter tracts to come into view. Inside the tracts, water can only move in a lengthwise direction, back and forth along the length of the thin strand. But in the rest of the brain tissue, the water can move around more freely.

In fact, U-M brain imaging specialists already use this kind of information to tell them if cancer cells are dying in response to chemotherapy or radiation, because water can move faster in dead or dying areas of cancer tissue than it can in healthy brain cells.

In tractography imaging, Mukherji explains, "How the water molecules are oriented, how they move, is something we can now detect, and as a result we can now see parts of the brain that we were never able to see before."

Add that together with the ability to create 3-D maps of the brain, and the result is spectacular images that just show the entire network of white-matter tracts and the individual nerve fibers that they're made of.

These images become a roadmap for surgeons like Sagher, especially when they're superimposed on other images that show the specific areas of "gray matter" where epileptic seizures begin or where tumors lurk.

This cross-registration, as it is called, fuses the information about the areas of the brain that the surgeon needs to remove or destroy in order to treat the patient's condition, with the information about what that the surgeon needs to avoid in order to preserve a patient's vision, for instance, or her ability to move her right arm.

Surgeons like Sagher can use these images in the operating room, and even have them fed digitally into the special eyepiece that they use to perform surgery on very tiny areas of the brain.

"The computers can decipher the direction of the fibers, and then assign a color to them so we know that this group of fibers belongs to this tract, which has this function by virtue of where it is," explains Sagher, who directs the U-M Image-Guided Surgery Program. "It essentially makes the invisible visible."

He contrasts this kind of imaging with what was used even a decade ago. Back then, the neurosurgeon might be able to have a series of CT (computed tomography) scans showing the structure of the brain in individual slices. These transparent films would be hung on a lightbox in the operating room, and give the surgeon a sense of what to expect when he or she cut into the patient's head.

Since that time, scanners have gotten better and the computers needed to create 3-D images have gotten more powerful, which has allowed surgeons to see the gray matter better and allow the computer to guide their hands to some extent. But only tractography allows them to see the white-matter tracts.

Now, he and his colleagues use the images to plan their operations ahead of time – for instance, when operating on a patient with epilepsy who has decided to have surgery after medicines have failed to control their seizures.

If the origin of the seizures is in a part of the brain that controls memory or learning, for example, the tracts that lead in and out of that area are key connectors that, if cut, can change the patient's life forever. And if a tumor is deep within the brain, the operation needed to get to it can cut across many important areas. But the tractography images can let the surgeon see areas where there aren't any tracts, and plan the route he or she will take to get to the area of the problem.

Mukherji, Sagher and their colleagues predict that tractography will change brain surgery and the way we see the brain's function forever, just like the first CT and MRI scans of the brain changed the diagnosis and treatment of many disorders. The team is pursuing research to improve the technique and show how it can best be used – and how it helps spare patients from unintended consequences.

"Instead of imaging the brain, we're essentially able to image the mind," says Mukherji. "We're able to image how a person's thoughts and brain impulses travel, and this is just the beginning."

Friday, March 23, 2007

Scientists on brink of breakthrough in MRI scanning





GRAEME SMITH March 22 2007

A quarter of a century ago an elderly Fraserburgh man with terminal cancer became the first in the world to undergo an MRI body scan in a development which has saved thousands of lives.

Now, just yards from that pioneering scanner, Aberdeen scientists and clinicians are on the brink of another global MRI breakthrough which could save thousands more.

A prototype of an MRI scanner has been developed which will help earlier diagnosis of cancer, Alzheimer's, and Parkinson's disease and multiple sclerosis. Now funding has been approved to build one which can be used in clinical trials.

Since the first scan to highlight the tumours on the patient's liver, MRI has become one of modern medicine's most important diagnostic tools all over the world.

The developments by Professor John Mallard and his team in 1980 earned Aberdeen University tens of millions of pounds and it is hoped the latest breakthrough could provide similar financial rewards.

Professor David Lurie and a team of university and industrial collaborators - physicists, engineers, chemists, biologists and medical scientists - have been awarded £2.5m from the Engineering and Physical Sciences Research Council to build the working scanner over the next four years.

Professor Lurie said standard MRI allows images from inside a patient's body to be taken using a single magnetic field which is set when the machine is installed. The new technique, which has proved successful in principle and in tissue trials, should allow images of the patient to be taken at several different magnetic fields.

"It's a bit like having at our disposal a hundred or more MRI scanners, each one operating at a different magnetic field - but all in the one scanner," said Professor Lurie.

"It will be of use in research and diagnosis into conditions such as Parkinson's disease, which involves proteins in the brain, Alzheimer's disease, which also involves proteins in the brain, multiple sclerosis and, potentially, cancer."

He said there was also potential for non-clinical uses, like measuring protein changes during food processing.


© All rights reserved. Reproduction in whole or in part without permission is prohibited.